Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2019

View Archived Issues

Targeting ATP6V1A subunit in the v-ATPase complex inhibits mTORC1 signaling and activates autophagy

Allogene Therapeutics initiates phase I study of ALLO-715

FDA approves Entresto for pediatric heart failure

AL-008 potentiates the antitumor effector functions of macrophages and dendritic cells

TERT gene fusions as novel biomarkers in metastatic Leydig cell tumors

Phase I safety and PK data presented for novel CXCR4 antagonist YF-H-2015005

Black Diamond Therapeutics describes preclinical activity of mutant EGFR/HER2 inhibitor BDTX-189

Universita degli Studi di Siena discovers new antivirals

New arginase inhibitors identified at Merck & Co.

Ethris and Munster University Hospital receive support for work in primary ciliary dyskinesia

Voronoi patents EGFR/JAK3 inhibitors

Free fatty acid receptor 4 agonists disclosed by Axxam

PARAGON-HF results for sacubitril/valsartan in heart failure with preserved ejection fraction

Liver-targeted uncouplers reverse type 2 diabetes, fatty liver in primates

FDA approves Descovy for HIV-1 PrEP

Arbutus discontinues development of AB-506 following cases of acute hepatitis

Healx collaborates with ICR to discover treatments for diffuse intrinsic pontine glioma

Prometheus Biosciences and Takeda collaborate to develop novel IBD therapies

Deinove studies DNV-3837 in phase II for C. difficile infection